Can a simple test predict the best migraine drug for you?

NCT ID NCT04503083

Completed Knowledge-focused Sponsor: IRCCS National Neurological Institute "C. Mondino" Foundation Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study aimed to find biological markers that could predict which migraine patients respond best to a new class of drugs called CGRP monoclonal antibodies. Researchers studied 243 adults with severe migraine, using genetic, brain imaging, and other tests. The goal is to personalize treatment, improve outcomes, and reduce healthcare costs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CGRP monoclonal antibodies
What this could lead to: If successful, this could help doctors predict which migraine patients will benefit from CGRP antibody treatments, saving time and money.
What could go wrong: This is an observational study, not a treatment trial. The biomarkers identified may not prove reliable in practice, and the results may not apply to all migraine patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MIGRAINE

Contacts and locations

Locations

Headache Research Group Vall d'Hebron Institute of Research

Barcelona, Catalonia, 8009, Spain
Headache Science Center

Pavia, 27100, Italy
Institut für Systemische Neurowissenschaften, Universitätsklinikum Hamburg-Eppendorf

Hamburg, 20357, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.